Human papillomavirus vaccine acceptability among a national sample of adult women in the USA

Sexual Health

Volumn 7, Issue 3, 2010, Pages 304-309

  Stupiansky, Nathan W ^a   Rosenthal, Susan L ^b   Wiehe, Sarah E ^a   Zimet, Gregory D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

acceptability; HPV; vaccination; women

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; EDUCATION; FEMALE; HEALTH CENTER; HISPANIC; HUMAN; INFLUENZA; MARRIAGE; NONHUMAN; OUTCOME ASSESSMENT; PHARMACY; POLITICS; RACE; RELIGION; SAMPLE; SEXUAL HEALTH; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; UNITED STATES; VACCINATION; WART VIRUS;

ADULT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INFLUENZA VACCINES; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; POLITICS; SEXUALLY TRANSMITTED DISEASES, VIRAL; SOCIOECONOMIC FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 77956028822     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH09127     Document Type: Article

References (22)

1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-819 doi:10.1001/jama.297.8.813 (Pubitemid 46333946)
2. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36: 6-10. doi:10.1363/3600604
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73. doi:10.1038/ sj.bjc.6600688
4. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113: 3036-3046
5. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. doi:10.1016/S1470-2045 (05)70101-70107
6. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 2007; 369: 2161-2170 doi:10.1016/S0140-6736(07)60946-5 (Pubitemid 46977438)
7. Hopenhayn C, Christian A, Christian W, Schoenberg N. Human papillomavirus vaccine: knowledge and attitudes in two Appalachian Kentucky counties. Cancer Causes Control 2007; 18: 627-634 doi:10.1007/s10552-007-9007-7 (Pubitemid 46883680)
8. Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL. Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 2009; 27: 1668-1673 doi:10.1016/j.vaccine. 2009.01.035
9. Ferris DG, Waller JL, Owen A, Smith J. HPV vaccine acceptance among mid-adult women. J Am Board Fam Med 2008; 21: 31-37 doi:10.3122/jabfm.2008.01. 070103 (Pubitemid 351159668)
10. Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007; 7: 304. doi:10.1186/1471-2458-7-304
11. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 2009; 48: 426-431 doi:10.1016/j.ypmed.2008.11.010
12. Schwarz TFS, Marek SA, Wysocki J, Galaj A, Perona P, Poncelet S, et al. Immunogenicity and tolerability of an HPV-16/18 AS04- adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27: 581-587 doi:10.1016/j.vaccine. 2008.10.088
13. Muñoz N, Ricardo M, Punee P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949-1957. doi:10.1016/S0140-6736(09)60691-7
14. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009; 45: 453-462 doi:10.1016/
15. Reece M, Sanders SA, Dodge B, Ghassemi A, Fortenberry JD. Prevalence and characteristics of vibrator use by men in the United States. J Sex Med 2009; 6: 1867-1874 doi:10.1111/j.1743-6109. 2009.01290.x
16. Herbenick DRM, Sanders S, Dodge B, Ghassemi A, Fortenberry JD. Prevalence and characteristics of vibrator use by women in the United States: results from a nationally representative study. J Sex Med 2009; 6: 1857-1866 doi:10.1111/j.1743-6109.2009.01318.x
17. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007; 40: 108-115 doi:10.1016/j.jadohealth.2006.10.007 (Pubitemid 46149373)
18. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45: 107-114 doi:10.1016/j.ypmed.2007.05.013 (Pubitemid 47348081)
19. Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS. Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, Southern women. J Rural Health 2009; 25: 93-97 doi:10.1111/j.1748- 0361.2009.00204.x
20. Scarinci IC, Garces-Palacio IC, Partridge EE. An examination of acceptability of HPV vaccination among African American women and Latina Immigrants. J Womens Health 2007; 16: 1224-1233 doi:10.1089/jwh.2006.0175 (Pubitemid 47587338)
21. Forster AS, Marlow LAV, Wardle J, Stephenson J, Waller J. Understanding adolescents intentions to have the HPV vaccine. Vaccine 2010; 28: 1673-1676 doi:10.1016/j.vaccine.2009.11.082
22. Skinner SR, Garland SM, Stanley MA, Pitts M, Quinn MA. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 2008; 188: 238-242